Bioasis Technologies Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOAF research report →
Price Chart
About the company
Bioasis Technologies Inc. is a developing biopharmaceutical enterprise dedicated to the discovery and advancement of treatments and diagnostic tools for various neurological conditions. Central to its strategy is the proprietary xB3 platform, an innovative technology designed to overcome the blood-brain barrier (BBB) and effectively deliver therapeutic agents to the central nervous system (CNS).
- CEO
- Deborah Ann Rathjen
- IPO
- 2010
- Employees
- 4
- HQ
- New Haven, CT, US
Get TickerSpark's AI analysis on BIOAF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.94K
- P/E
- -0.12
- PEG
- -0.01
- P/S
- 10.53
- P/B
- -0.19
- EV/EBITDA
- -0.16
- Div Yield
- 0.00%
- Gross Margin
- -45.57%
- Op Margin
- -12956.07%
- Net Margin
- -7846.50%
- ROE
- 392.02%
- ROIC
- -494.10%
Latest fiscal year · YoY change
- Revenue
- $37.73K-99.1%
- Gross Profit
- $-1,188,430-141.8%
- Op Income
- $-4,822,936
- Net Income
- $-2,960,092-523.8%
- EPS
- $-0.04-498.1%
- OCF Growth
- -305.2%
- FCF Growth
- -305.2%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.74
- RSI (14)
- 0
- Avg Volume
- 68.08K
No earnings-call transcripts are available for BIOAF yet.
- Free Float
- 98.3%
- Shares Outstanding
- 79.41M
- Float Shares
- 78.07M
Our BIOAF coverage
Recent articles, reports, and earnings notes.
No research on BIOAF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIOAF report →Financial Analysis: Prelude Therapeutics (NASDAQ:PRLD) versus Bioasis Technologies (OTCMKTS:BIOAF)
defenseworld.net · Apr 27
Bioasis to Attend Upcoming Industry Conferences
globenewswire.com · Sep 30
Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor
globenewswire.com · Aug 18
Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfatase
globenewswire.com · Aug 9
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
globenewswire.com · Jul 29
Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager
globenewswire.com · Jul 20
Bioasis Technologies reports positive results from an efficacy study of its blood-brain barrier penetrant
proactiveinvestors.com · Jul 7
Bioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple Sclerosis
globenewswire.com · Jul 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.